A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial - Johnson, David W.; Pascoe, Elaine M.; Badve, Sunil V.; Dalziel, Kim; Cass, Alan; Clarke, Philip; Ferrari, Paolo; McDonald, Stephen P.; Morrish, Alicia T.; Pedagogos, Eugenie; Perkovic, Vlado; Reidlinger, Donna; et al. (American journal of kidney diseases, 2015)
Keywords: Adult; Aged; Anemia; Anemia - blood; Anemia - drug therapy; Anemia - etiology; chronic kidney disease (CKD); Cost Savings; darbepoetin; dialysis; Double-Blind Method; Drug Monitoring - methods; Drug Resistance - drug effects; drug sensitivity; Drug Synergism; epoetin; Erythropoiesis - drug effects; erythropoiesis-stimulating agent (ESA); erythropoietin; Erythropoietin - administration & dosage; Erythropoietin - adverse effects; ESA hyporesponsiveness; ESA resistance index (ERI); Hematologic Agents - administration & dosage; Hematologic Agents - adverse effects; hemoglobin; Hemoglobins - analysis; Humans; Middle Aged; Nephrology; pentoxifylline; Pentoxifylline - administration & dosage; Pentoxifylline - adverse effects; Quality of Life; randomized controlled trial; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - economics; Renal Insufficiency, Chronic - psychology; Vasodilator Agents - administration & dosage; Vasodilator Agents - adverse effects; dialysis; drug sensitivity; Anemia; ESA hyporesponsiveness; chronic kidney disease (CKD); hemoglobin; randomized controlled trial; erythropoiesis-stimulating agent (ESA); epoetin; pentoxifylline; darbepoetin; ESA resistance index (ERI); erythropoietin